Experimental Hematology & Oncology

Article	Citations
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms	267
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity	201
Inhibition of EYA family tyrosine phosphatase activity reveals a therapeutic vulnerability and enhances Menin and DOT1L inhibitor efficacy in KMT2A-rearranged leukemia	167
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	161
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	138
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	137
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting	119
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	117
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	117
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	112
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	99
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy	97
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	94
Correction: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma	93
Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmu	93
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	91
From Amphiphiles to mRNA platforms: emerging vaccination strategies for pancreatic cancer	88
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	79
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	76
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	74
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	71
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	70
Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy	69
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	68
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	68

ISX–TWIST1 reprograms CD47–inflammasome signaling to reshape the immune microenvironment in liver cancer	66
Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting	64
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	61
Role of m6A writers, erasers and readers in cancer	58
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	58
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	57
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	54
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	54
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	54
Breast cancer heterogeneity and its implication in personalized precision therapy	52
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	52
The novel retinoid WYC-209 sensitizes multiple myeloma to carfilzomib via epigenetically upregulating ZMYND8	51
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	51
Three-dimensional chromatin landscapes in MLLr AML	48
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma	48
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	45
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	45
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	45
TCR engineered T cells for solid tumor immunotherapy	44
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	43
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	43
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	42
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	41
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	41
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination	40
Correction: Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	39
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma	39
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia	39
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	39
Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities	38
Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma	38
Matrix stiffness induces Ca2+-DCLK1-PIP5K1A mechanotransduction as a context-specific amplifier in pancreatic cancer progression and chemotherapy resistance	38
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	37
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response	36
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs	36
Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells	36
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances	36
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis	36
Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study	36
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors	35
The clinical impact of IKZF1 mutation in acute myeloid leukemia	35
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy	35
Antibody-drug conjugates in breast cancer: current evidence and future directions	34
A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression	34
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights	33
KMT2A alterations in acute myeloid leukemia: a proposed genetic risk model and transplantation outcomes	33
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	33
Versatile function of NF-ĸB in inflammation and cancer	32
Recent advances and future perspectives in the therapeutics of prostate cancer	32
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review	32

Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance	32
Immunotherapy in breast cancer: current landscape and emerging trends	32
New exploration of KRASG12D inhibitors and the mechanisms of resistance	31
Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012–2021: a systematic analysis	31
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy	30
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma	29
Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	29
FGL1-mediated lymph node metastasis in stage T1 non-small cell lung cancer: therapeutic targeting	29
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia	28
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma	28
A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia	28
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications	28
Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer	28
Validation of a microRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer classification, available through the open app BladdermiRaCan	27
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study	27
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy	27
Engineered extracellular vesicles displaying bi-specific T-cell engagers for targeted therapy of B-cell malignancies	27
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity	27
Decoding the spatiotemporal characteristics of ferroptosis: reshaping tumour therapeutic strategies	27
Downregulation of pro-surfactant protein B contributes to the recurrence of early-stage non-small cell lung cancer by activating PGK1-mediated Akt signaling	27
Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms	27
Sarcosine sensitizes lung adenocarcinoma to chemotherapy by dual activation of ferroptosis via PDK4/PDHA1 signaling and NMDAR-mediated iron export	26
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	26
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	26
Immunotherapy in chronic lymphocytic leukemia: advances and challenges	26
The roles of tissue resident macrophages in health and cancer	25
Obesity- and tumor-derived signals drive cancer-associated state transitions in breast mesenchymal stromal/stem cells reprogrammed by IL1RA or JAK inhibition	25
Efficacy of melflufen in multiple myeloma with mutated or deleted TP53	25
Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-	25
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	24
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer	23
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	23
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	23
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates	22
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma	22
Crosstalk between ferroptosis and extracellular vesicles in cancer: from interaction to clinical application	22
Epigenetic and post-translational regulatory networks of ferroptosis in the tumor immune microenvironment	22
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	21
In vivo CAR-T engineering: insights from the 2025 ASH annual meeting	21
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA	21
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies	21
Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases	21
Molecular background of Philadelphia chromosome dependent enhancement of cellular growth and tyrosine kinase inhibitor sensitivity	21
Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution	21
An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo	20
Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults	20
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	20
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance	20
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities	20
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications	20
ELK1 promotes the progress of myeloid leukemia by hindering the differentiation of neutrophils	19
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	19
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies	19
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer	19
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies	19
Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy	19
Anti-tumor vaccine efficacy depends on adjuvant type and associates with induced IgG subclass and glycosylation profiles	19
In-depth insight into tumor-infiltrating stromal cells linked to tertiary lymphoid structures and their prospective function in cancer immunotherapy	19
Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial	18
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer	18
ZMIZ2 facilitates hepatocellular carcinoma progression via LEF1 mediated activation of Wnt/β-catenin pathway	18
YAP-induced MAML1 cooperates with STAT3 to drive hepatocellular carcinoma progression	18
Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting	18
Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting	18
CDCA8 induced by NF-YA promotes hepatocellular carcinoma progression by regulating the MEK/ERK pathway	18
The lncRNA PARylator promotes PARP1 activation and resistance to DNA‑damaging therapy in esophageal squamous cell carcinoma	18
Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021	18
Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles	18
Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy	18
TLR7/8 signaling activation enhances the potency of human pluripotent stem cell-derived eosinophils in cancer immunotherapy for solid tumors	17
CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy	17
Revealing the role of the gut microbiota in enhancing targeted therapy efficacy for lung adenocarcinoma	17
Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma	17
A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma	17
The role of organoids in cancer research	17
CUL4B-DDB1-COP1-mediated UTX downregulation promotes colorectal cancer progression	17
MMP14 from BM-MSCs facilitates progression and Ara-C resistance in acute myeloid leukemia via the JAK/STAT pathway	17
Role of CDK4 as prognostic biomarker in Soft Tissue Sarcoma and synergistic effect of its inhibition in dedifferentiated liposarcoma sequential treatment	16
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy	16
Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases	16

Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting	16
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies	16
Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells	16
A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer	16
RNA binding proteins in MLL-rearranged leukemia	16
Pan-cancer transcriptional atlas of minimal residual disease links DUSP1 to chemotherapy persistence	16
Identification of adenoid subtype characterized with immune-escaped phenotype in lung squamous carcinoma based on transcriptomics	16
The genomic analysis brings a new piece to the molecular jigsaw of idiopathic erythrocytosis	16
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study	16
Spatial ecostructural modelling of endometrial cancer identifies the key role of CD90 + CD105 + endothelial cells in tumour heterogeneity and predicts disease recurrence	15
Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines	15
Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects	15
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era	15
Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a	15
The influence of neuro-tumor interactions on tumorigenesis and therapeutic response	15
Reconstructed colorectal cancer model to dissect the anti-tumor effect of mesenchymal stromal cells derived extracellular vesicles	15
AOH1996 targets mitochondrial dynamics and metabolism in leukemic stem cells via mitochondrial PCNA inhibition	15
Organoids for disease modeling and treatment: state-of-the-art	15
Chimeric antigen receptor modified hematopoietic stem cells (CAR-HSCs) arm all immune forces for anti-tumor in mice	14
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials	14
TRIM family contribute to tumorigenesis, cancer development, and drug resistance	14
Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets	14
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers	14
RHO GTPase family in hepatocellular carcinoma	14
Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer	14
A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease	14
Prospects and advances of PROTAC in the treatment of hematologic malignancies	13
Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer	13
Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting	13
Current insight into the regulation of PD-L1 in cancer	13
CAR-T cell combination therapies in hematologic malignancies	13
ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells	13
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer	13
Secretogranin II influences the assembly and function of MHC class I in melanoma	13
Unravelling neutropenic enterocolitis: insights from gut microbiota, and intestinal barrier analyses	13
GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment	13
Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma	13
LINP1 represses unfolded protein response by directly inhibiting eIF2α phosphorylation to promote cutaneous squamous cell carcinoma	13
Analysis of CD20 and PD-L1 levels on small extracellular vesicles (sEV) produced by DLBCL cells and EBV-transformed B cells, and potential role in T cell inhibition	13
ANXA6/TRPV2 axis promotes lymphatic metastasis in head and neck squamous cell carcinoma by inducing autophagy	13
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect	12
Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China	12
Radiation-induced exosomal miR-21 enhances tumor proliferation and invasiveness in breast cancer: implications for poor prognosis in radiotherapy patients	12
Molecular profiling of skin cells identifies distinct cellular signatures in radiation-induced skin injury across various stages in the murine dataset	12
Identification of a novel NPM1 mutation in acute myeloid leukemia	12
Exploring coding and signal joints of novel TCR beta D-D rearrangements for tracking T-cell leukemia clonality	12
The gut microbiota as a booster for radiotherapy: novel insights into radio-protection and radiation injury	12
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses	12
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition	12
Recent advances and challenges of cellular immunotherapies in lung cancer treatment	12
Multi-omics analyses of the heterogenous immune microenvironment in triple-negative breast cancer implicate UQCRFS1 potentiates tumor progression	12
Mutation rates in main tumour driver genes predict prognosis in patients with superficial spreading or nodular primary melanoma: results from the CARAMEL study by the Italian Melanoma Intergroup (IMI)	12
Transfer RNA-derived small RNA: an emerging small non-coding RNA with key roles in cancer	12
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy	12
Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma	12
RNA-based co-transfer of human CD8αβ with WT1-specific TCRαβ redirects tumor recognition by CD4 and γδ T-cells towards MHC class I-restricted WT1 epitopes and boosts CD8 T-cell responses with or witho	12
Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities	12
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment	12
Genetic factors, risk prediction and AI application of thrombotic diseases	11
The clinical landscape of CAR NK cells	11
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment	11
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia	11
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting	11
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers	11
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting	11
Bisecting GlcNAc enhances CD8+ T cell-mediated killing of breast cancer by suppressing PD-L1 expression and its binding to PD-1	11
Inhibition of protein kinase CK2 remodels the tumor immune microenvironment and sensitizes lung cancer to PD-L1 blockade	11
Thioredoxin-1 regulates self-renewal and differentiation of murine hematopoietic stem cells through p53 tumor suppressor	11
Targeting metabolic reprogramming in chronic lymphocytic leukemia	11
Natural killer cell-based cancer immunotherapy: from basics to clinical trials	11
Single-cell profiling reveals FAM117A as a key regulator linking macrophage–epithelial crosstalk with the progression of lung adenocarcinoma	11
Current and future therapies for follicular lymphoma	11
Targeting NOTCH1 in combination with antimetabolite drugs prolongs life span in relapsed pediatric and adult T-acute lymphoblastic leukemia xenografts	11
Targeting CD22 for B-cell hematologic malignancies	11
Tumor-intrinsic PD-L1 drives lung cancer progression in response to TLR stimulation by promoting autophagy through the TRAF6–BECN1 signaling axis	11
Prophylactic infusion of allogeneic double-negative T cells as immune modulators to prevent relapse in high-risk AML patients post-Allo-HSCT: a phase I trial	11
p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma	11
Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer	10
Developments in nanotechnology approaches for the treatment of solid tumors	10
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsul	10
New approaches to idiopathic neutropenia in the era of clonal hematopoiesis	10
Targeting collagen to optimize cancer immunotherapy	10
New insight into circRNAs: characterization, strategies, and biomedical applications	10
Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer	10
CD105+CAF-derived exosomes CircAMPK1 promotes pancreatic cancer progression by activating autophagy	10
Increasing cure rates of solid tumors by immune checkpoint inhibitors	10
Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments	10
Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer	10
CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity	10
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion	10
Bone marrow sympathetic neuropathy is a hallmark of hematopoietic malignancies and it involves severe ultrastructural damage	9
Targeting platelet-tumor cell interactions via thromboxane A2-prostanoid receptor blockade to reduce metastasis in triple negative breast cancer	9
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling	9
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner	9
Targeting the integrated stress response in hematologic malignancies	9